-
Lung Cancer: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Dyspnea in lung cancer patients: a systematic review
Review
(2157) Views (742) Full article downloads
Authors: Ganesan Kathiresan, Reynold F Clement, Meera T Sankaranarayanan
Published Date November 2010
Volume 2010:1(Default) Pages 141 - 150
DOI: http://dx.doi.org/10.2147/LCTT.S14426
Ganesan Kathiresan1, Reynold F Clement2, Meera T Sankaranarayanan21Department of Physiotherapy, School of Allied Health, Masterskill University College, Sabah, Malaysia; 2Department of Biological Sciences, Essex University, Colchester, UK
Abstract: Dyspnea is a common and distressing symptom experienced by 19%–51% of patients with advanced cancer. Higher incidences are reported in patients approaching end of life. While the prevalence of dyspnea has been reported to be as frequent as pain in people with lung cancer, less attention has been paid to the distress associated with dyspnea. This review of the literature was undertaken to investigate how dyspnea has been assessed and whether breathlessness in people with lung cancer is distressing. Using a predetermined search strategy and inclusion criteria, 31 primary studies were identified and included in this review. Different outcome measures were used to assess the experience of dyspnea, with domains including intensity, distress, quality of life, qualitative sensation, and prevalence. Overall, the studies report a high prevalence of dyspnea in lung cancer patients, with subjects experiencing a moderate level of dyspnea intensity and interference with activities of daily living. Distress associated with breathing appears to be variable, with some studies reporting dyspnea to be the most distressing sensation, and others reporting lower levels of distress. However, taking into account the prevalence, intensity, and distress of dyspnea, the general consensus appears to be that the experience of dyspnea in people with lung cancer is common, with varying degrees of intensity, but involves considerable unpleasantness. Thus, if dyspnea and pain are both distressing sensations for people with lung cancer, this has potential implications for both clinical and academic areas with regards to both management strategies and further research.
Keywords: breathlessness, distress, neoplasm, scale, fatigue
Readers of this article also read:
Drug resistance in lung cancer
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
Afatinib treatment in advanced non-small cell lung cancer
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma




